TY - JOUR
T1 - CTL response and protection against P815 tumor challenge in mice immunized with DNA expressing the tumor-specific antigen P815A
AU - Rosato, Antonio
AU - Zambon, Annalisa
AU - Milan, Gabriella
AU - Ciminale, Vincenzo
AU - D'Agostino, Donna M.
AU - Macino, Beatrice
AU - Zanovello, Paola
AU - Collavo, Dino
PY - 1997
Y1 - 1997
N2 - A DNA immunization approach was used to induce an immune response against the tumor-specific antigen P815A in DBA/2 mice. The PIA gene, which encodes the P815A antigen, was modified by the addition of a short sequence coding for a tag epitope recognized by the monoclonal antibody AU1, and cloned into the eukaryotic expression vector pBKCMV, resulting in plasmid pBKCMV-P1A. L1210 cells stably transfected with pBKCMV-P1A expressed P1A mRNA and were lysed by the syngeneic P815A-specific cytotoxic clone CTL-P1:5, thus confirming that the tag-modified P1A protein underwent correct processing and presentation. A single intramuscular injection of 100 μg of pBKCMV-P1A induced the expression of P1A mRNA for at least 4 months. Eighty percent of DBA/2 mice injected three times with 100 μg of pBKCMV-P1A generated cytotoxic T lymphocytes (CTL) that lysed P815 tumor cells, whereas mock-inoculated animals failed to show any cytotoxicity. Moreover, experiments designed to evaluate the protection of pBKCMV-P1A-immunized mice against a lethal challenge with P815 tumor cells showed that 6 of 10 immunized mice rejected the tumor, and 2 mice showed prolonged survival compared to control animals.
AB - A DNA immunization approach was used to induce an immune response against the tumor-specific antigen P815A in DBA/2 mice. The PIA gene, which encodes the P815A antigen, was modified by the addition of a short sequence coding for a tag epitope recognized by the monoclonal antibody AU1, and cloned into the eukaryotic expression vector pBKCMV, resulting in plasmid pBKCMV-P1A. L1210 cells stably transfected with pBKCMV-P1A expressed P1A mRNA and were lysed by the syngeneic P815A-specific cytotoxic clone CTL-P1:5, thus confirming that the tag-modified P1A protein underwent correct processing and presentation. A single intramuscular injection of 100 μg of pBKCMV-P1A induced the expression of P1A mRNA for at least 4 months. Eighty percent of DBA/2 mice injected three times with 100 μg of pBKCMV-P1A generated cytotoxic T lymphocytes (CTL) that lysed P815 tumor cells, whereas mock-inoculated animals failed to show any cytotoxicity. Moreover, experiments designed to evaluate the protection of pBKCMV-P1A-immunized mice against a lethal challenge with P815 tumor cells showed that 6 of 10 immunized mice rejected the tumor, and 2 mice showed prolonged survival compared to control animals.
UR - http://www.scopus.com/inward/record.url?scp=0030778940&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030778940&partnerID=8YFLogxK
M3 - Article
C2 - 9287145
AN - SCOPUS:0030778940
VL - 8
SP - 1451
EP - 1458
JO - Human Gene Therapy
JF - Human Gene Therapy
SN - 1043-0342
IS - 12
ER -